NASDAQ:SLDB - Solid Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.45 +0.09 (+0.96 %) (As of 04/25/2019 04:00 PM ET)Previous Close$9.36Today's Range$9.04 - $9.4752-Week Range$5.97 - $54.84Volume252,315 shsAverage Volume374,019 shsMarket Capitalization$334.72 millionP/E RatioN/ADividend YieldN/ABeta1.83 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Receive SLDB News and Ratings via Email Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLDB Previous Symbol CUSIPN/A CIK1707502 Webwww.solidbio.com Phone617-337-4680Debt Debt-to-Equity Ratio0.01 Current Ratio10.31 Quick Ratio10.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.53 per share Price / Book2.68Profitability EPS (Most Recent Fiscal Year)($2.25) Net Income$-74,800,000.00 Net MarginsN/A Return on Equity-49.58% Return on Assets-46.14%Miscellaneous Employees111 Outstanding Shares35,420,000Market Cap$334.72 million Next Earnings Date5/9/2019 (Estimated) OptionableOptionable Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions What is Solid Biosciences' stock symbol? Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB." How were Solid Biosciences' earnings last quarter? Solid Biosciences Inc (NASDAQ:SLDB) issued its quarterly earnings results on Wednesday, March, 13th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.09. View Solid Biosciences' Earnings History. When is Solid Biosciences' next earnings date? Solid Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Solid Biosciences. What price target have analysts set for SLDB? 7 Wall Street analysts have issued 1 year target prices for Solid Biosciences' shares. Their forecasts range from $8.00 to $57.00. On average, they anticipate Solid Biosciences' share price to reach $33.60 in the next year. This suggests a possible upside of 255.6% from the stock's current price. View Analyst Price Targets for Solid Biosciences. What is the consensus analysts' recommendation for Solid Biosciences? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences. What are Wall Street analysts saying about Solid Biosciences stock? Here are some recent quotes from research analysts about Solid Biosciences stock: 1. According to Zacks Investment Research, "Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts. " (3/19/2019) 2. Chardan Capital analysts commented, "We increase our SLDB PT to $60 (from $37.50) on recent reports of efficacy shown for AAV-based gene therapies (GTs) in Duchenne muscular dystrophy (DMD) across several ongoing trials, including Solid’s trial. Our PT increase is also driven by the 18 June announced resolution of the clinical hold on SGT-001. We believe early patient reports (see bullets below) suggest breakthroughs could be in progress for AAV- based gene therapies for DMD being developed by Therapeutics (unrated), and Pfizer (unrated). Positive early data from clinical trials from 3 different companies, to us, supports the utility of microdystrophin GT in a devastating disease with no effective approved therapies. therefore update our Chardan DMD Model (discussed below; see Figure 1), which drives our SLDB PT increase to $60." (6/24/2018) Has Solid Biosciences been receiving favorable news coverage? News coverage about SLDB stock has trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Solid Biosciences earned a news impact score of 1.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. Are investors shorting Solid Biosciences? Solid Biosciences saw a increase in short interest in the month of April. As of April 15th, there was short interest totalling 3,673,820 shares, an increase of 34.1% from the March 29th total of 2,738,752 shares. Based on an average trading volume of 338,396 shares, the short-interest ratio is presently 10.9 days. Approximately 17.0% of the company's stock are short sold. View Solid Biosciences' Current Options Chain. Who are some of Solid Biosciences' key competitors? Some companies that are related to Solid Biosciences include Rubius Therapeutics (RUBY), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Autolus Therapeutics (AUTL), Coherus Biosciences (CHRS), GENFIT S A/ADR (GNFT), Twist Bioscience (TWST), BioCryst Pharmaceuticals (BCRX), Cellectis (CLLS), NanoString Technologies (NSTG), Vericel (VCEL), Nightstar Therapeutics (NITE), Voyager Therapeutics (VYGR), BAVARIAN NORDIC/S (BVNRY) and Osiris Therapeutics (OSIR). What other stocks do shareholders of Solid Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include SUMMIT THERAPEU/S (SMMT), Progenics Pharmaceuticals (PGNX), Selecta Biosciences (SELB), Exelixis (EXEL), Fate Therapeutics (FATE), Ocular Therapeutix (OCUL), Sorrento Therapeutics (SRNE), Verastem (VSTM), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX). Who are Solid Biosciences' key executives? Solid Biosciences' management team includes the folowing people: Dr. Andrey Juan Zarur, Co-Founder & Chairman of Directors (Age 48)Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 45)Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 47)Dr. Carl Ashley Morris, Chief Scientific Officer (Age 49)Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48) When did Solid Biosciences IPO? (SLDB) raised $130 million in an initial public offering on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers. Who are Solid Biosciences' major shareholders? Solid Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Matisse Capital (0.19%) and Virtu Financial LLC (0.06%). Company insiders that own Solid Biosciences stock include Boxer Capital, Llc, Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Life Sciences Maste Perceptive, Matthew Bennett Arnold and Pedro Alvaro Amorrortu. View Institutional Ownership Trends for Solid Biosciences. Which institutional investors are buying Solid Biosciences stock? SLDB stock was bought by a variety of institutional investors in the last quarter, including Matisse Capital and Virtu Financial LLC. View Insider Buying and Selling for Solid Biosciences. How do I buy shares of Solid Biosciences? Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Solid Biosciences' stock price today? One share of SLDB stock can currently be purchased for approximately $9.45. How big of a company is Solid Biosciences? Solid Biosciences has a market capitalization of $334.72 million. The company earns $-74,800,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe. What is Solid Biosciences' official website? The official website for Solid Biosciences is http://www.solidbio.com. How can I contact Solid Biosciences? Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680. MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 138 (Vote Outperform)Underperform Votes: 117 (Vote Underperform)Total Votes: 255MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/25/2019 by MarketBeat.com StaffFeatured Article: Do back-end load funds outperform no-load funds?